PhoreMost

PhoreMost is a private biotechnology company pioneering a novel approach to early-stage drug discovery by combining sophisticated phenotypic screening with AI to illuminate new therapeutic pathways, particularly in oncology. Its proprietary platform, SITESEEKER®, is designed to identify and validate previously inaccessible drug targets, enabling the development of first-in-class medicines. The company advances its own pipeline while also engaging in strategic partnerships to expand the reach and impact of its technology. As a pre-revenue, pre-clinical stage entity, its success hinges on translating platform hits into viable clinical candidates and securing continued partnership and investment funding.

Proprietary SITESEEKER® platform combining next-generation phenotypic screening using protein fragment libraries with AI-driven target deconvolution to identify novel druggable sites and therapeutic starting points.

PhoreMost competes in the crowded AI/tech-enabled drug discovery sector with companies like Exscientia, Recursion, and BenevolentAI. Its differentiation lies in its specific focus on phenotypic screening with protein fragments and AI-driven target identification, rather than purely computational design. It also competes for partnership deals with established discovery service providers and academic technology transfer offices.